CGEN Stock - Compugen Ltd

CGEN Stock Chart

CGEN Profile

Compugen Ltd., headquartered in Holon, Israel, is a pioneering clinical-stage company dedicated to advancing therapeutic discovery and development across global markets, including Israel, the United States, and Europe. Established in 1993, Compugen specializes in researching, developing, and commercializing a robust pipeline of therapeutic and product candidates. The company's focus lies in immuno-oncology, where it leads with innovative approaches to combat solid tumors through a range of promising treatments.

At the forefront of Compugen's immuno-oncology pipeline are several key candidates. These include COM701, an anti-PVRIG antibody currently undergoing Phase I clinical trials for the treatment of solid tumors. Additionally, COM902, a therapeutic antibody targeting TIGIT, is in Phase I clinical studies for advanced malignancies, while Bapotulimab targets ILDR2 and is also in Phase I clinical trials for solid tumors. Compugen is further exploring AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, in Phase I/II studies for advanced non-small cell lung cancer. Beyond these, the company's early-stage programs concentrate on myeloid targets, reflecting its commitment to diverse approaches in cancer treatment.

Compugen's collaborative efforts bolster its research and development capabilities significantly. The company has established partnerships with industry leaders such as Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca to accelerate the development and commercialization of antibody-based therapeutics. These collaborations underscore Compugen's strategic approach to leveraging cutting-edge science and expanding its global footprint in the competitive landscape of immuno-oncology.

CGEN Revenue Chart

CGEN Earnings

Analyst Ratings